“A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes”

por Gupta, Deepali, Ogden, Sean B., Shankar, Kripa, Varshney, Salil, Zigman, Jeffrey M.
Publicado 2020

OR12-04 LEAP2 Deletion Does Not Counteract The Effects Of Ghrelin Deletion During Insulin-Induced-Hypoglycemia

por Shankar, Kripa, Varshney, Salil, Gupta, Deepali, Singh, Omprakash, Ogden, Sean B, Osborne-Lawrence, Sherri, Metzger, Nathan P, Richard, Corine P, Marc Zigman, Jeffrey
Publicado 2023

THU309 Ghrelin Deficiency Does Not Improve Glucose Tolerance And Insulin Secretion In Female Mice

por Gupta, Deepali, Shankar, Kripa, Varshney, Salil, Singh, Omprakash, Paul, Subhojit, Ogden, Sean B, Osborne-Lawrence, Sherri, Burstein, Avi W, Metzger, Nathan P, Richard, Corine P, Zigman, Jeffrey M
Publicado 2023

LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue

por Shankar, Kripa, Metzger, Nathan P., Singh, Omprakash, Mani, Bharath K., Osborne-Lawrence, Sherri, Varshney, Salil, Gupta, Deepali, Ogden, Sean B., Takemi, Shota, Richard, Corine P., Nandy, Karabi, Liu, Chen, Zigman, Jeffrey M.
Publicado 2021